Phathom Pharmaceuticals, Inc.PHAT

Phathom Pharmaceuticals Inc. (PHAT) is a clinical-stage company with one marketed product-VOQUEZNA® (vonoprazan) tablets-and one revenue stream. The company’s latest 10-Q shows net product revenues of $58.3 million for the quarter ended 31 March 2026, up from $28.5 million in the same period a year ago, but the headline growth masks a widening cash haemorrhage: net loss attributable to parent of $30.4 million, operating loss of $15.5 million, and operating cash outflows of $15.6 million. Cash and equivalents at 31 March 2026 stood at $180.9 million against liabilities of $642.1 million and shareholders’ equity of negative $337.0 million.

The company markets VOQUEZNA as a potassium-competitive acid blocker for acid-related gastrointestinal disorders, with the only current revenue coming from U.S. sales of VOQUEZNA, VOQUEZNA DUAL PAK and VOQUEZNA TRIPLE PAK, which launched in the fourth quarter of 2023. Phathom’s product pages and pipeline notes stress vonoprazan’s position versus lansoprazole in acid-related GI disorders and highlight an ongoing Phase 2 study in eosinophilic oesophagitis (EoE), pHalcon-EoE-201, which completed enrolment on 23 June 2026. If the Phase 2 results are positive, the company says it may discuss paediatric development with regulators to extend regulatory exclusivity.

Filings show that vonoprazan’s commercial story is still being written. The company’s 10-Q confirms net product revenues of $58.3 million for Q1 2026 versus $28.5 million for Q1 2025, but also discloses that the only revenue source is U.S. sales of VOQUEZNA products. Under its Revenue Interest Financing Agreement, investors are entitled to a 10% royalty on net sales of vonoprazan-containing products. Research and development expense was $7.8 million in Q1 2026, inventory net $6.5 million, and capitalised capex was a trivial $61,000. Weighted average diluted shares outstanding were 82.1 million for the quarter.

For a deeper look at the clinical pipeline, see the company’s Clinical Trial & Pipeline page, which outlines Phathom’s development program across non-erosive GERD and EoE and frames vonoprazan’s mechanism versus PPI comparators. The product portfolio page outlines VOQUEZNA’s positioning and supply-chain integrity via Authorized Distributors of Record, aiming to curb counterfeit exposure.

On the ownership front, a Schedule 13G/A filed on 20 July 2026 updates institutional ownership disclosures, while the 8-K dated 23 June 2026 confirms completion of enrolment in the EoE Phase 2 study. As of 25 July 2026, the company’s SEC filings index and submissions JSON provide the primary source rail for financials and events. The company’s XBRL company facts JSON offers structured disclosure of key financial metrics and line items.

What remains unproven is whether vonoprazan can sustain formulary access and pricing power in the U.S. market. There is no evidence here that a second revenue stream is imminent; the pipeline is preclinical and early-phase. Investors are effectively betting on a single product’s uptake in a crowded acid-reflux segment while the company continues to burn cash at a rate that would make a venture capitalist wince. The next catalyst would be Phase 2 EoE data readout and any FDA dialogue about paediatric development; until then, the story is still a bet on one pill’s market life.